A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose ...

Investing.com - Leerink Partners heeft dinsdag het koersdoel voor DexCom (NASDAQ:DXCM) verhoogd naar $ 92,00 van $ 81,00, terwijl het Outperform-advies voor de fabrikant van continue glucosemonitoring ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...

Dexcom, Inc. (NASDAQ: DXCM), wereldwijd een marktleider op het gebied van real-time continue glucosemonitoring (rt-CGM), heeft aangekondigd dat Dexcom G7 nu in Nederland rechtstreeks verbinding kan ...

DexCom , Inc. (NASDAQ:DXCM) released its second quarter 2025 earnings presentation on July 30, highlighting continued revenue growth and key product developments. The continuous glucose monitoring ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Investing.com - Raymond James heeft zijn Zeker kopen-rating voor Jabil (NYSE:JBL) herhaald met een koersdoel van $ 260,00.

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The ...